DGAP-News: MorphoSys AG / Key word(s): Miscellaneous04.06.2021 / 19:32 The issuer is solely responsible for the content of this announcement.Media ReleaseMorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refract.
/PRNewswire/ Novartis today announced robust data from the primary analysis of the pivotal Phase II ELARA trial of Kymriah® (tisagenlecleucel) in patients.
BRUKINSA demonstrated superior objective response rate by investigator assessment in the planned interim analysisBRUKINSA was associated with a statistically significant lower risk of atrial fibrillation or flutter Company to host investor call and webcast on Friday, June 11 at noon ETCAMBRIDGE, Mass. & BEIJING (BU.
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral.